A new AI model replaces months of simulation with near-instant predictions, changing how spacecraft operations are prepared
Updated
April 24, 2026 10:53 AM

Northrop Grumman Stargaze serves as the mother ship for the Pegasus, an air-launched orbital rocket. PHOTO: UNSPLASH
Flexcompute, a startup that builds software to simulate real-world physics, is working with Northrop Grumman to change how space missions are prepared. Together, they have developed an AI-based system that can predict how spacecraft respond during critical manoeuvres such as docking—when one spacecraft moves in and connects with another in orbit. These steps have traditionally taken months of preparation.
At the centre of this work is a long-standing problem in space operations. When a spacecraft fires its thrusters, the exhaust plume interacts with nearby surfaces. These interactions can affect movement, temperature and stability. Because these effects are difficult to test in real conditions, engineers have relied on large volumes of computer simulations to estimate outcomes before a mission. That process is slow and resource-intensive.
The new system replaces much of that workflow with a trained AI model. Instead of running millions of simulations, the model learns patterns from physics-based data and can make predictions in seconds. It also provides a measure of uncertainty, which helps engineers understand how reliable those predictions are when making decisions.
"At Northrop Grumman, we're pioneering physics AI to accelerate design and solve complex simulation and modelling problems like plume impingement—critical for station keeping, rendezvous and space robotics. Simply put: we're pushing the boundaries of advanced space operations", said Fahad Khan, Director of AI Foundations at Northrop Grumman. "Partnering with Flexcompute and NVIDIA, we're accelerating innovation and mission timelines to deliver superior space capabilities for customers at the speed they need".
The system is built using technology from NVIDIA, which provides the computing framework behind the model. Flexcompute has adapted it to handle the specific challenges of spaceflight, including how gases expand and interact in a vacuum. The result is a tool that can simulate complex scenarios much faster while maintaining the level of accuracy needed for mission planning.
By shortening preparation time, the model changes how engineers approach spacecraft design and operations. Faster predictions mean teams can test more scenarios and adjust plans more quickly. It also helps improve fuel use and extend the lifespan of spacecraft.
"Northrop Grumman's confidence reflects what sets Flexcompute apart", said Vera Yang, President and Co-Founder of Flexcompute. "We are able to take the most accurate and scalable physics foundations and evolve them into highly trained, customized Physics AI solutions that engineers can rely on. This work shows how we are transforming the role of simulation, not just speeding it up, but expanding what engineers can confidently solve and how quickly they can act".
The collaboration points to a broader shift in how engineering problems are being handled. Instead of relying only on detailed simulations that take time to run, companies are beginning to use AI systems that can approximate those results quickly while still reflecting the underlying physics.
"The industry's most ambitious space missions now demand a level of speed and precision that traditional engineering cycles can no longer sustain", said Tim Costa, vice president and general manager of computational engineering at NVIDIA. "By integrating NVIDIA PhysicsNeMo, Northrop Grumman and Flexcompute are transforming complex simulations like plume impingement from days of compute into seconds of insight, drastically accelerating the path from mission concept to orbit".
What emerges from this work is a shift in how missions are prepared. When prediction cycles move from months to seconds, testing and decision-making can happen faster. For space operations, where timing and precision are closely linked, that change could reshape how systems are built and run.
Keep Reading
A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM

Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.